Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

PCOS: Symptoms, Risks & GLP-1 Treatment

glpverdict

Subscribe Sign in

Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content

GLP-1 evidence for polycystic ovary syndrome

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
GLP-1 therapy improves insulin sensitivity in PCOS Source: Reproductive Biology & Endocrinology, 2023 (opens in a new tab) Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial	BModerate evidence	Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial
GLP-1 weight loss restores ovulatory cycles in some patients Observational + small trial data; ovulation rate ~30-50% higher than controls	BModerate evidence	Observational + small trial data; ovulation rate ~30-50% higher than controls
GLP-1 directly treats hyperandrogenism (acne, hirsutism) Effect appears secondary to weight loss + insulin improvement, not androgen-specific	CLimited evidence	Effect appears secondary to weight loss + insulin improvement, not androgen-specific
GLP-1 is FDA-approved for PCOS No FDA-approved indication for PCOS; use is off-label, weight-driven	FNo evidence	No FDA-approved indication for PCOS; use is off-label, weight-driven

Polycystic ovary syndrome(PCOS)

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for polycystic ovary syndrome

Related GLP-1 medications

Mounjaro

Wegovy

Ozempic

Common questions readers ask

Sources